Endothelial dysfunction: from physiology to therapy

Area of Science:

• Cardiovascular Biology
• Endothelial Function
• Vascular Medicine

Background:

• The endothelium regulates vascular smooth muscle tone via vasodilator mediators.
• Endothelial dysfunction is a hallmark of many vascular diseases, including atherosclerosis.
• Key endothelial factors include nitric oxide (NO), prostacyclin, and endothelium-derived hyperpolarizing factors (EDHF).

Purpose of the Study:

• To summarize the mechanisms of endothelial dysfunction.
• To elucidate the role of angiotensin-converting enzyme (ACE) in endothelial function and dysfunction.
• To highlight the therapeutic potential of ACE inhibitors in restoring endothelial vasodilator function.

Main Methods:

• Review of existing literature on endothelial function and dysfunction.
• Analysis of the roles of nitric oxide, prostacyclin, EDHF, bradykinin, and angiotensin II.
• Examination of the impact of endothelial dysfunction on vascular tone, architecture, and cell interactions.

Main Results:

• Endothelial dysfunction involves impaired mediator release, increased constrictors, and reduced smooth muscle sensitivity.
• Angiotensin-converting enzyme (ACE) controls bradykinin and angiotensin II levels, impacting endothelial function.
• Angiotensin II contributes to endothelial dysfunction by inducing resistance to NO, while bradykinin promotes vasodilation.

Conclusions:

• ACE inhibitors can counteract endothelial dysfunction by potentiating bradykinin, promoting vasodilator release.
• Restoration of endothelial vasodilator function by ACE inhibitors helps prevent platelet aggregation and leukocyte recruitment.
• Understanding endothelial dysfunction mechanisms is crucial for developing effective cardiovascular therapies.